CA2958685A1 - Targeting k-ras-mediated signaling pathways and malignancy by anti-hlif antibodies - Google Patents

Targeting k-ras-mediated signaling pathways and malignancy by anti-hlif antibodies Download PDF

Info

Publication number
CA2958685A1
CA2958685A1 CA2958685A CA2958685A CA2958685A1 CA 2958685 A1 CA2958685 A1 CA 2958685A1 CA 2958685 A CA2958685 A CA 2958685A CA 2958685 A CA2958685 A CA 2958685A CA 2958685 A1 CA2958685 A1 CA 2958685A1
Authority
CA
Canada
Prior art keywords
lif
ras
cancer
agent
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2958685A
Other languages
English (en)
French (fr)
Inventor
Frank Mccormick
Man-Tzu WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA2958685A1 publication Critical patent/CA2958685A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2958685A 2014-09-10 2015-09-10 Targeting k-ras-mediated signaling pathways and malignancy by anti-hlif antibodies Abandoned CA2958685A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048770P 2014-09-10 2014-09-10
US62/048,770 2014-09-10
PCT/US2015/049461 WO2016040657A1 (en) 2014-09-10 2015-09-10 TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES

Publications (1)

Publication Number Publication Date
CA2958685A1 true CA2958685A1 (en) 2016-03-17

Family

ID=55459579

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2958685A Abandoned CA2958685A1 (en) 2014-09-10 2015-09-10 Targeting k-ras-mediated signaling pathways and malignancy by anti-hlif antibodies

Country Status (7)

Country Link
US (1) US20170247446A1 (OSRAM)
EP (1) EP3191129A4 (OSRAM)
JP (1) JP2017527582A (OSRAM)
CN (1) CN106687134A (OSRAM)
AU (1) AU2015314980A1 (OSRAM)
CA (1) CA2958685A1 (OSRAM)
WO (1) WO2016040657A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
EP3407820A4 (en) 2016-01-26 2019-11-06 Cyberdontics, Inc. Automated dental treatment system
MX2019007376A (es) 2016-12-19 2020-02-07 Mosaic Biomedicals S L U Anticuerpos contra el lif y usos de los mismos.
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
JP7423598B2 (ja) * 2018-04-12 2024-01-29 メドイミューン・リミテッド がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ
WO2019215512A1 (en) 2018-05-10 2019-11-14 Cyberdontics Inc. Automated dental drill
CN112638941A (zh) * 2018-05-14 2021-04-09 免疫医疗有限公司 针对lif的抗体及其剂量形式
WO2019243900A2 (en) * 2018-06-18 2019-12-26 Mosaic Biomedicals Slu Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
WO2020219668A1 (en) * 2019-04-24 2020-10-29 Memorial Sloan Kettering Cancer Center Compositions and methods for treating ras-mutant cancers
EP4208122A4 (en) 2020-09-03 2024-09-11 Perceptive Technologies, Inc. METHOD AND DEVICE FOR CNA ANALYSIS OF DENTAL ANATOMY

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
KR20140126357A (ko) * 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
EP3049110A2 (en) * 2013-09-23 2016-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for targeting tumor microenvironment and for preventing metastasis

Also Published As

Publication number Publication date
AU2015314980A1 (en) 2017-03-02
EP3191129A4 (en) 2018-03-14
JP2017527582A (ja) 2017-09-21
EP3191129A1 (en) 2017-07-19
WO2016040657A1 (en) 2016-03-17
US20170247446A1 (en) 2017-08-31
CN106687134A (zh) 2017-05-17

Similar Documents

Publication Publication Date Title
US20170247446A1 (en) TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
EP2880447B1 (en) Markers associated with sensitivity to inhibitors of human double minute 2 (mdm2)
US20130042333A1 (en) Markers for cancer prognosis and therapy and methods of use
AU2004291709A1 (en) Process
CA2828959A1 (en) Methods and compositions for predicting response to eribulin
KR20100095571A (ko) 암 환자에서의 진단 목적용 방법 및 조성물
ES3005230T3 (en) Diagnostic and therapeutic methods for the treatment of rheumatoid arthritis (ra)
US20210363593A1 (en) CXCL13 Marker For Predicting Immunotherapeutic Responsiveness In Patient With Lung Cancer And Use Thereof
Vogt et al. p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer
WO2021104442A1 (en) Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
US20220249660A1 (en) Compositions and methods for treating lung, colorectal and breast cancer
EP2169077A1 (en) Methods and compositions for diagnosing an adenocarcinoma
US20220002396A1 (en) Methods of treating cancer with farnesyltransferase inhibitors
US20110151469A1 (en) Interferon epsilon (ifne1) as a marker for targeted cancer therapy
WO2015170105A1 (en) Method for predicting renal cell carcinoma (rcc)
Pei et al. Molecular subtyping and precision therapy for esophageal cancer
US20170003292A1 (en) Paxip1 as a biomarker for wee1 inhibitor therapy
KR102800733B1 (ko) 담도암의 예방 또는 치료용 조성물
KR102615451B1 (ko) Her2 양성 유방암 치료 예후 예측용 신규 바이오마커 및 이의 용도
US20250082600A1 (en) Treating haematological malignancies by means of satraplatin
KR102326119B1 (ko) 암의 면역 치료 후 예후 예측용 바이오 마커
US20250002918A1 (en) Compositions and methods for treatment of mic60 depleted cancers and metastasis
Györffy Resistance-associated signatures in breast cancer
TW202231280A (zh) 抑制胃癌腫瘤生長或判斷胃癌腫瘤生長階段之方法
Haley Triple negative breast cancer: a paradox or Pandora's box

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211201

FZDE Discontinued

Effective date: 20211201